'Podnosis': A deep dive into the OTC approval of Narcan, the opioid overdose drug

26 Jul 2023
www.fiercehealthcare.com
Drug Approval
'Podnosis': A deep dive into the OTC approval of Narcan, the opioid overdose drug
Preview
Source: FierceHealthcare
None
This week, we'll introduce you to our sister podcast, "The Top Line."
On March 29, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner continues our miniseries to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives.
To learn more about the topics in this episode:
Emergent makes history with first FDA nod for over-the-counter naloxone
Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts
Adapt tests ads urging opioid users' loved ones to stock Narcan at home
Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M
Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod
Virtual Roundtable: Remote Therapeutic Monitoring, The Future of Virtual Care Management
"The Top Line" and "Podnosis" are produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.